{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:35:07Z","timestamp":1793039707944,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Angelini S.p.A."},{"name":"Universit\u00e0 Commerciale Luigi Bocconi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40261-021-01000-1","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T03:03:01Z","timestamp":1615258981000},"page":"303-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6330-0591","authenticated-orcid":false,"given":"Carla","family":"Rognoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Bertolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Jommi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"1000_CR1","unstructured":"DSM-5 [Internet]. [cited 2020 Apr 25]. https:\/\/www.psychiatry.org\/psychiatrists\/practice\/dsm. Accessed 1 Jan 2021."},{"key":"1000_CR2","doi-asserted-by":"crossref","unstructured":"Matei VP, Mihailescu A, Paraschiv G, Al-Bataineh R, Purnichi T. Weight gain and antipsychotics. Data from eufest study. Acta Endocrinol Buchar Rom 2005. 2016;12:177\u201384.","DOI":"10.4183\/aeb.2016.177"},{"key":"1000_CR3","first-page":"1163","volume":"13","author":"MC Mauri","year":"2014","unstructured":"Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163\u201391.","journal-title":"EXCLI J."},{"key":"1000_CR4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","volume":"63","author":"PB Jones","year":"2006","unstructured":"Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079\u201387.","journal-title":"Arch Gen Psychiatry"},{"key":"1000_CR5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927\u201342.","journal-title":"Am J Psychiatry"},{"key":"1000_CR6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74:686\u201393.","journal-title":"JAMA Psychiatry."},{"key":"1000_CR7","first-page":"208","volume":"18","author":"T Kishimoto","year":"2019","unstructured":"Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry Off J World Psychiatr Assoc WPA. 2019;18:208\u201324.","journal-title":"World Psychiatry Off J World Psychiatr Assoc WPA."},{"key":"1000_CR8","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HGG, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;CD006569.","DOI":"10.1002\/14651858.CD006569.pub3"},{"key":"1000_CR9","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PSS, Kissling W, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;CD006627.","DOI":"10.1002\/14651858.CD006627.pub2"},{"key":"1000_CR10","doi-asserted-by":"crossref","unstructured":"Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;CD006324.","DOI":"10.1002\/14651858.CD006324.pub2"},{"key":"1000_CR11","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;CD006624.","DOI":"10.1002\/14651858.CD006624.pub2"},{"key":"1000_CR12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/schbul\/sbp163","volume":"36","author":"J Wang","year":"2010","unstructured":"Wang J, Omori IM, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. Schizophr Bull. 2010;36:229\u201330.","journal-title":"Schizophr Bull"},{"key":"1000_CR13","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.euroneuro.2006.06.003","volume":"16","author":"DW Haupt","year":"2006","unstructured":"Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol. 2006;16:S149\u201355.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1000_CR14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64\u201377.","journal-title":"Lancet Psychiatry."},{"key":"1000_CR15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet Lond Engl. 2019;394:939\u201351.","journal-title":"Lancet Lond Engl."},{"key":"1000_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second-generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123:225\u201333.","journal-title":"Schizophr Res"},{"key":"1000_CR17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12888-017-1539-0","volume":"17","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017;17:373.","journal-title":"BMC Psychiatry."},{"key":"1000_CR18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","volume":"40","author":"L Hirsch","year":"2017","unstructured":"Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40:771\u201381.","journal-title":"Drug Saf"},{"key":"1000_CR19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/acps.12439","volume":"132","author":"B Stubbs","year":"2015","unstructured":"Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand. 2015;132:144\u201357.","journal-title":"Acta Psychiatr Scand"},{"key":"1000_CR20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler H-G, Goettsch W, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26:1033\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1000_CR21","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;21:339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535.","DOI":"10.1136\/bmj.b2535"},{"key":"1000_CR22","unstructured":"IQVIA Home Solutions sticky hovers.\u00a0http:\/\/view.ceros.com\/quintiles-ims\/iqvia-home-solutions-2-1. Accessed 1 Jan 2021."},{"key":"1000_CR23","unstructured":"Chapter 9: Summarizing study characteristics and preparing for synthesis.\u00a0https:\/\/training.cochrane.org\/handbook\/current\/chapter-09. Accessed 1 Jan 2021."},{"key":"1000_CR24","doi-asserted-by":"publisher","unstructured":"Burns R.B., Dobson C.B. (1981) Standard error of the difference between means. In: Experimental Psychology. Springer, Dordrecht. https:\/\/doi.org\/10.1007\/978-94-011-7241-7_15.","DOI":"10.1007\/978-94-011-7241-7_15"},{"key":"1000_CR25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1000_CR26","doi-asserted-by":"crossref","unstructured":"Aromataris E,\u00a0Munn Z\u00a0(Editors).\u00a0JBI Manual for Evidence Synthesis. JBI, 2020. Available from https:\/\/synthesismanual.jbi.global.\u00a0Accessed 1 Jan 2021.","DOI":"10.46658\/JBIMES-20-01"},{"key":"1000_CR27","unstructured":"Guidelines and Measures| Agency for Healthcare Research and Quality. https:\/\/www.ahrq.gov\/gam\/index.html. Accessed 1 Jan 2021."},{"key":"1000_CR28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1751-7893.2010.00163.x","volume":"4","author":"RC Josiassen","year":"2010","unstructured":"Josiassen RC, Shaughnessy RA, Filymer DM, Donohue AM, Kacso M, Finkel N, et al. Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study. Early Interv Psychiatry. 2010;4:57\u201363.","journal-title":"Early Interv Psychiatry."},{"key":"1000_CR29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1440-1819.2009.02039.x","volume":"64","author":"H-Y Lee","year":"2010","unstructured":"Lee H-Y, Ham B-J, Kang R-H, Paik J-W, Hahn S-W, Lee M-S, et al. Trial of aripiprazole in the treatment of first-episode schizophrenia. Psychiatry Clin Neurosci. 2010;64:38\u201343.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1000_CR30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.pnpbp.2010.12.003","volume":"35","author":"S-Y Lee","year":"2011","unstructured":"Lee S-Y, Park M-H, Patkar AA, Pae C-U. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:490\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1000_CR31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hup.2270","volume":"27","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Dai G. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52\u00a0weeks follow-up in China. Hum Psychopharmacol. 2012;27:605\u201314.","journal-title":"Hum Psychopharmacol"},{"key":"1000_CR32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pnpbp.2012.09.010","volume":"40","author":"Y Takekita","year":"2013","unstructured":"Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, et al. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:110\u20134.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1000_CR33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/13651501.2011.653376","volume":"17","author":"KC Jindal","year":"2013","unstructured":"Jindal KC, Singh GP, Munjal V. Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India. Int J Psychiatry Clin Pract. 2013;17:21\u20139.","journal-title":"Int J Psychiatry Clin Pract."},{"key":"1000_CR34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2014.05.040","volume":"157","author":"H Li","year":"2014","unstructured":"Li H, Luo J, Wang C, Xie S, Xu X, Wang X, et al. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. Schizophr Res. 2014;157:112\u20139.","journal-title":"Schizophr Res"},{"key":"1000_CR35","first-page":"758212","volume":"2014","author":"DH Adams","year":"2014","unstructured":"Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez J-C. Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treat. 2014;2014:758212.","journal-title":"Schizophr Res Treat."},{"key":"1000_CR36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12291-013-0415-z","volume":"29","author":"A Gupta","year":"2014","unstructured":"Gupta A, Dadheech G, Yadav D, Sharma P, Gautam S. Metabolic issues in schizophrenic patients receiving antipsychotic treatment. Indian J Clin Biochem. 2014;29:196\u2013201.","journal-title":"Indian J Clin Biochem"},{"key":"1000_CR37","first-page":"339","volume":"26","author":"S Zhang","year":"2014","unstructured":"Zhang S, Lan G. Prospective 8-week trial on the effect of olanzapine, quetiapine, and aripiprazole on blood glucose and lipids among individuals with first-onset schizophrenia. Shanghai Arch Psychiatry. 2014;26:339\u201346.","journal-title":"Shanghai Arch Psychiatry."},{"key":"1000_CR38","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Iglesias R, Ortiz-Garcia de la Foz V, Mart\u00ednez Garc\u00eda O, Amado JA, Garcia-Unzueta MT, Ayesa-Arriola R, et al. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12\u00a0weeks of treatment in first treated episode of psychosis. Schizophr Res. 2014;159:90\u20134.","DOI":"10.1016\/j.schres.2014.07.045"},{"key":"1000_CR39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S2215-0366(16)00085-7","volume":"3","author":"G Gr\u00fcnder","year":"2016","unstructured":"Gr\u00fcnder G, Heinze M, Cordes J, M\u00fchlbauer B, Juckel G, Schulz C, et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry. 2016;3:717\u201329.","journal-title":"Lancet Psychiatry."},{"key":"1000_CR40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.schres.2016.04.036","volume":"174","author":"A Malla","year":"2016","unstructured":"Malla A, Mustafa S, Rho A, Abadi S, Lepage M, Joober R. Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: a one-year outcome study. Schizophr Res. 2016;174:120\u20135.","journal-title":"Schizophr Res"},{"key":"1000_CR41","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2147\/NDT.S121588","volume":"12","author":"T Kishi","year":"2016","unstructured":"Kishi T, Matsuda Y, Matsunaga S, Mukai T, Moriwaki M, Tabuse H, et al. A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. Neuropsychiatr Dis Treat. 2016;12:3041\u20139.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"1000_CR42","first-page":"1073","volume":"15","author":"PBS Kumar","year":"2017","unstructured":"Kumar PBS, Pandey RS, Thirthalli J, Kumar PTS, Kumar CN. A comparative study of short term efficacy of aripiprazole and risperidone in schizophrenia. Curr Neuropharmacol. 2017;15:1073\u201384.","journal-title":"Curr Neuropharmacol"},{"key":"1000_CR43","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.3889\/oamjms.2019.403","volume":"7","author":"DR Turangan","year":"2019","unstructured":"Turangan DR, Loebis B, Husada SM, Nasution NM. Differences of fasting blood glucose level in people with schizophrenia between before and after getting aripiprazole treatment. Open Access Maced J Med Sci. 2019;7:2607\u201311.","journal-title":"Open Access Maced J Med Sci."},{"key":"1000_CR44","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/0269881119872193","volume":"33","author":"Z Cheng","year":"2019","unstructured":"Cheng Z, Yuan Y, Han X, Yang L, Cai S, Yang F, et al. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: eight-week outcomes. J Psychopharmacol Oxf Engl. 2019;33:1227\u201336.","journal-title":"J Psychopharmacol Oxf Engl."},{"key":"1000_CR45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12888-019-2103-x","volume":"19","author":"S Mustafa","year":"2019","unstructured":"Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, et al. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC Psychiatry. 2019;19:114.","journal-title":"BMC Psychiatry."},{"key":"1000_CR46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euroneuro.2020.08.009","volume":"39","author":"J V\u00e1zquez-Bourgon","year":"2020","unstructured":"V\u00e1zquez-Bourgon J, Ib\u00e1\u00f1ez Alario M, Mayoral-van Son J, G\u00f3mez Revuelta M, Ayesa Arriola R, Juncal Ruiz M, et al. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: a pragmatic clinical trial in first episode psychosis patients. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2020;39:46\u201355.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol."},{"issue":"4","key":"1000_CR47","first-page":"2888","volume":"13","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang X, Jiang Z, Li H. Effects on social functioning and metabolism in the patients with first-episode schizophrenia: aipiprazole vs risperidone. Int J Clin Exp Med. 2020;13(4):2888\u201394.","journal-title":"Int J Clin Exp Med."},{"key":"1000_CR48","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","volume":"168","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168:957\u201367.","journal-title":"Am J Psychiatry"},{"key":"1000_CR49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.04.008","volume":"132","author":"SG Potkin","year":"2011","unstructured":"Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132:101\u20137.","journal-title":"Schizophr Res"},{"key":"1000_CR50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","volume":"225","author":"M Ogasa","year":"2013","unstructured":"Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology. 2013;225:519\u201330.","journal-title":"Psychopharmacology"},{"key":"1000_CR51","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","volume":"47","author":"HA Nasrallah","year":"2013","unstructured":"Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670\u20137.","journal-title":"J Psychiatr Res"},{"key":"1000_CR52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","volume":"145","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80\u00a0mg\/day and 160\u00a0mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101\u20139.","journal-title":"Schizophr Res"},{"key":"1000_CR53","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/2045125315606027","volume":"5","author":"SG Potkin","year":"2015","unstructured":"Potkin SG, Kimura T, Guarino J. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol. 2015;5:322\u201331.","journal-title":"Ther Adv Psychopharmacol."},{"key":"1000_CR54","first-page":"e12352","volume":"11","author":"T Higuchi","year":"2019","unstructured":"Higuchi T, Ishigooka J, Iyo M, Yeh C-B, Ebenezer EG, Liang KY, et al. Lurasidone in the treatment of schizophrenia: results of a double-blind, placebo-controlled trial in Asian patients. Asia-Pac Psychiatry Off J Pac Rim Coll Psychiatr. 2019;11:e12352.","journal-title":"Asia-Pac Psychiatry Off J Pac Rim Coll Psychiatr."},{"key":"1000_CR55","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1007\/s00213-020-05628-3","volume":"237","author":"M Jena","year":"2020","unstructured":"Jena M, Mishra A, Mishra BR, Nath S, Maiti R. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial. Psychopharmacology. 2020;237:3471\u201380.","journal-title":"Psychopharmacology"},{"key":"1000_CR56","doi-asserted-by":"crossref","unstructured":"Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147:95\u2013102.","DOI":"10.1016\/j.schres.2013.03.013"},{"key":"1000_CR57","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1017\/S1092852915000917","volume":"21","author":"CU Correll","year":"2016","unstructured":"Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectr. 2016;21:393\u2013402.","journal-title":"CNS Spectr"},{"key":"1000_CR58","doi-asserted-by":"publisher","unstructured":"Patel PJ, Weidenfeller C, Jones AP, Nilsson J, Hsu J. Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study. Neurol Ther. 2020. https:\/\/doi.org\/10.1007\/s40120-020-00221-4.","DOI":"10.1007\/s40120-020-00221-4"},{"key":"1000_CR59","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1185\/03007990903102966","volume":"25","author":"J Karagianis","year":"2009","unstructured":"Karagianis J, Williams R, Davis L, Procyshyn R, Monga N, Hanley J, et al. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. Curr Med Res Opin. 2009;25:2121\u201332.","journal-title":"Curr Med Res Opin"},{"key":"1000_CR60","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.euroneuro.2009.03.003","volume":"19","author":"D Novick","year":"2009","unstructured":"Novick D, Haro JM, Perrin E, Suarez D, Texeira JM. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2009;19:542\u201350.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol."},{"key":"1000_CR61","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","volume":"70","author":"RC Smith","year":"2009","unstructured":"Smith RC, Lindenmayer J-P, Davis JM, Kelly E, Viviano TF, Cornwell J, et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry. 2009;70:1501\u201313.","journal-title":"J Clin Psychiatry"},{"key":"1000_CR62","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/WNF.0b013e3181f0ec33","volume":"33","author":"M Gilles","year":"2010","unstructured":"Gilles M, Hentschel F, Paslakis G, Glahn V, Lederbogen F, Deuschle M. Visceral and subcutaneous fat in patients treated with olanzapine: a case series. Clin Neuropharmacol. 2010;33:248\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"1000_CR63","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.pnpbp.2010.04.003","volume":"34","author":"C-C Chiu","year":"2010","unstructured":"Chiu C-C, Chen C-H, Chen B-Y, Yu S-H, Lu M-L. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:866\u201370.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1000_CR64","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/0269881108101783","volume":"24","author":"C Bushe","year":"2010","unstructured":"Bushe C, Sniadecki J, Bradley AJ, Poole Hoffmann V. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol Oxf Engl. 2010;24:1001\u20139.","journal-title":"J Psychopharmacol Oxf Engl."},{"key":"1000_CR65","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.schres.2010.04.001","volume":"120","author":"RC Smith","year":"2010","unstructured":"Smith RC, Lindenmayer J-P, Hu Q, Kelly E, Viviano TF, Cornwell J, et al. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Schizophr Res. 2010;120:204\u20139.","journal-title":"Schizophr Res"},{"key":"1000_CR66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.schres.2011.04.005","volume":"130","author":"M Krakowski","year":"2011","unstructured":"Krakowski M, Czobor P. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res. 2011;130:27\u201333.","journal-title":"Schizophr Res"},{"key":"1000_CR67","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/schbul\/sbp037","volume":"37","author":"KP Grootens","year":"2011","unstructured":"Grootens KP, van Veelen NMJ, Peuskens J, Sabbe BGC, Thys E, Buitelaar JK, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37:352\u201361.","journal-title":"Schizophr Bull"},{"key":"1000_CR68","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4088\/JCP.10m05997","volume":"72","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J Clin Psychiatry. 2011;72:1602\u201310.","journal-title":"J Clin Psychiatry"},{"key":"1000_CR69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JCP.0b013e31820fcea3","volume":"31","author":"E Fernandez-Egea","year":"2011","unstructured":"Fernandez-Egea E, Miller B, Garcia-Rizo C, Bernardo M, Kirkpatrick B. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol. 2011;31:154\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"1000_CR70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-0031-1280793","volume":"44","author":"NRB Raposo","year":"2011","unstructured":"Raposo NRB, Ferreira AS, Gattaz WF. Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol. Pharmacopsychiatry. 2011;44:169\u201372.","journal-title":"Pharmacopsychiatry."},{"key":"1000_CR71","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-0031-1297935","volume":"45","author":"G Paslakis","year":"2012","unstructured":"Paslakis G, Deuschle M, Thome J, R\u00fcsse S, Kopf D. The differential effect of risperidone and olanzapine on insulin sensitivity after 3\u00a0weeks of treatment: a HOMA pilot study. Pharmacopsychiatry. 2012;45:96\u20139.","journal-title":"Pharmacopsychiatry."},{"key":"1000_CR72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pnpbp.2011.11.004","volume":"36","author":"I Kusumi","year":"2012","unstructured":"Kusumi I, Honda M, Uemura K, Sugawara Y, Kohsaka M, Tochigi A, et al. Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:313\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1000_CR73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/POR.S26552","volume":"3","author":"D Novick","year":"2012","unstructured":"Novick D, Ascher-Svanum H, Haro JM, Bertsch J, Takahashi M. Schizophrenia Outpatient Health Outcomes study: twelve-month findings. Pragmatic Obs Res. 2012;3:27\u201340.","journal-title":"Pragmatic Obs Res."},{"key":"1000_CR74","first-page":"488","volume":"53","author":"J Kaushal","year":"2012","unstructured":"Kaushal J, Bhutani G, Gupta R. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone. Singapore Med J. 2012;53:488\u201392.","journal-title":"Singapore Med J"},{"key":"1000_CR75","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/JCP.0b013e31825cccad","volume":"32","author":"A Schreiner","year":"2012","unstructured":"Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsog P, Salinas R, et al. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol. 2012;32:449\u201357.","journal-title":"J Clin Psychopharmacol"},{"key":"1000_CR76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JCP.0b013e31823f880a","volume":"32","author":"RW Buchanan","year":"2012","unstructured":"Buchanan RW, Panagides J, Zhao J, Phiri P, den Hollander W, Ha X, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32:36\u201345.","journal-title":"J Clin Psychopharmacol"},{"key":"1000_CR77","first-page":"196","volume":"45","author":"J Schoemaker","year":"2012","unstructured":"Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry. 2012;45:196\u2013203.","journal-title":"Pharmacopsychiatry."},{"key":"1000_CR78","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4321\/S0213-61632012000400004","volume":"26","author":"E \u00c1lvarez","year":"2012","unstructured":"\u00c1lvarez E, Bernardo M, Guti\u00e9rrez Casares JR, Montejo \u00c1L. Ziprasidone versus Olanzapine in the weight gain associated with the treatment of schizophrenia: a six-month double-blind randomized parallel group study. Eur J Psychiatry. 2012;26:248\u201359.","journal-title":"Eur J Psychiatry."},{"key":"1000_CR79","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00213-012-2850-6","volume":"225","author":"J-J Ou","year":"2013","unstructured":"Ou J-J, Xu Y, Chen H-H, Fan X, Gao K, Wang J, et al. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology. 2013;225:627\u201335.","journal-title":"Psychopharmacology"},{"key":"1000_CR80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-013-3073-1","volume":"230","author":"S Hu","year":"2013","unstructured":"Hu S, Yao M, Peterson BS, Xu D, Hu J, Tang J, et al. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and \u03b2-cell function in schizophrenic patients. Psychopharmacology. 2013;230:3\u201313.","journal-title":"Psychopharmacology"},{"key":"1000_CR81","doi-asserted-by":"crossref","unstructured":"Salviato Balb\u00e3o M, Cec\u00edlio Hallak JE, Arcoverde Nunes E, Homem de Mello M, Triffoni-Melo A de T, Ferreira FI de S, et al. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Ther Adv Psychopharmacol. 2014;4:30\u20136.","DOI":"10.1177\/2045125313507738"},{"key":"1000_CR82","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4103\/0253-7613.140579","volume":"46","author":"BK Choure","year":"2014","unstructured":"Choure BK, Gosavi D, Nanotkar S. Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study. Indian J Pharmacol. 2014;46:493\u20137.","journal-title":"Indian J Pharmacol."},{"key":"1000_CR83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000437430","volume":"72","author":"M Fabrazzo","year":"2015","unstructured":"Fabrazzo M, Monteleone P, Prisco V, Perris F, Catapano F, Tortorella A, et al. Olanzapine is faster than haloperidol in inducing metabolic abnormalities in schizophrenic and bipolar patients. Neuropsychobiology. 2015;72:29\u201336.","journal-title":"Neuropsychobiology."},{"key":"1000_CR84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4314\/ijmu.v11i2.5","volume":"11","author":"S Singh","year":"2016","unstructured":"Singh S, Chandra S, Kapoor AK, Singh HK, Kant R. Metabolic effects of Olanzapine versus Iloperidone: a 24\u00a0weeks randomized, prospective, interventional study. Internet J Med Update EJOURNAL. 2016;11:17\u201324.","journal-title":"Internet J Med Update EJOURNAL."},{"key":"1000_CR85","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4103\/0019-5545.192016","volume":"58","author":"PN Suresh Kumar","year":"2016","unstructured":"Suresh Kumar PN, Anish PK, Rajmohan V. Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. Indian J Psychiatry. 2016;58:311\u20136.","journal-title":"Indian J Psychiatry."},{"key":"1000_CR86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.schres.2017.01.004","volume":"185","author":"C-H Lin","year":"2017","unstructured":"Lin C-H, Wang F-C, Lin S-C, Huang Y-H, Chen C-C. A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia. Schizophr Res. 2017;185:80\u20137.","journal-title":"Schizophr Res"},{"key":"1000_CR87","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pnpbp.2017.10.021","volume":"81","author":"M Huang","year":"2018","unstructured":"Huang M, Yu L, Pan F, Lu S, Hu S, Hu J, et al. A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:122\u201330.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"1000_CR88","first-page":"245","volume":"37","author":"S Ullah","year":"2018","unstructured":"Ullah S, Subhan F, Sultan SM, Muhammad A, Rauf K, Ali G, Shah R. Comparative Evaluation of Controlled Release Tablets Versus Reference Tablets of Olanzapine for Therapeutic Efficacy and Clinical Safety in Schizophrenic Patients. Lat. Am. J. Pharm. 2018;37(2):245\u201353.","journal-title":"Lat. Am. J. Pharm."},{"key":"1000_CR89","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1177\/0269881118780011","volume":"32","author":"DP Osborn","year":"2018","unstructured":"Osborn DP, Petersen I, Beckley N, Walters K, Nazareth I, Hayes J. Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: cohort study in THIN, a UK primary care database. J Psychopharmacol Oxf Engl. 2018;32:1098\u2013103.","journal-title":"J Psychopharmacol Oxf Engl."},{"key":"1000_CR90","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","volume":"176","author":"WF Martin","year":"2019","unstructured":"Martin WF, Correll CU, Weiden PJ, Jiang Y, Pathak S, DiPetrillo L, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176:457\u201367.","journal-title":"Am J Psychiatry"},{"key":"1000_CR91","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/JCP.0000000000001259","volume":"40","author":"E Moghimi Sarani","year":"2020","unstructured":"Moghimi Sarani E, Memari E, Anushiravani A, Mowla A. Is sitagliptin effective for modulating metabolic disturbances associated with olanzapine in schizophrenia patients? A double-blind placebo-controlled clinical trial. J Clin Psychopharmacol. 2020;40:487\u201390.","journal-title":"J Clin Psychopharmacol"},{"key":"1000_CR92","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3389\/fphar.2020.00739","volume":"11","author":"J Huang","year":"2020","unstructured":"Huang J, Hei G-R, Yang Y, Liu C-C, Xiao J-M, Long Y-J, et al. Increased appetite plays a key role in olanzapine-induced weight gain in first-episode schizophrenia patients. Front Pharmacol. 2020;11:739.","journal-title":"Front Pharmacol."},{"key":"1000_CR93","doi-asserted-by":"crossref","first-page":"109945","DOI":"10.1016\/j.pnpbp.2020.109945","volume":"101","author":"V de Almeida","year":"2020","unstructured":"de Almeida V, Alexandrino GL, Aquino A, Gomes AF, Murgu M, Dobrowolny H, et al. Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2020;101:109945.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1000_CR94","doi-asserted-by":"crossref","unstructured":"Potkin SG, Kunovac J, Silverman BL, Simmons A, Jiang Y, DiPetrillo L, et al. Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 study. J Clin Psychiatry. 2020;81.","DOI":"10.4088\/JCP.19m12769"},{"key":"1000_CR95","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.schres.2019.09.015","volume":"215","author":"F Guan","year":"2020","unstructured":"Guan F, Zhang T, Han W, Zhu L, Ni T, Lin H, et al. Relationship of SNAP25 variants with schizophrenia and antipsychotic-induced weight change in large-scale schizophrenia patients. Schizophr Res. 2020;215:250\u20135.","journal-title":"Schizophr Res"},{"key":"1000_CR96","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pnpbp.2012.06.024","volume":"39","author":"K-S Na","year":"2012","unstructured":"Na K-S, Kim W-H, Jung H-Y, Ryu SG, Min KJ, Park K-C, et al. Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:295\u2013300.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1000_CR97","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/08039488.2014.996252","volume":"69","author":"A \u00dc\u00e7ok","year":"2015","unstructured":"\u00dc\u00e7ok A, Saka MC, Bilici M. Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: an open-label, single-arm, flexible-dose, 12-months follow-up study. Nord J Psychiatry. 2015;69:426\u201332.","journal-title":"Nord J Psychiatry"},{"key":"1000_CR98","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2147\/NDT.S161186","volume":"14","author":"C-Y Chen","year":"2018","unstructured":"Chen C-Y, Tang T-C, Chen T-T, Bai YM, Tsai H-H, Chen H-L, et al. Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan. Neuropsychiatr Dis Treat. 2018;14:725\u201332.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"1000_CR99","doi-asserted-by":"crossref","unstructured":"Chen C-H, Lin T-Y, Chen T-T, Chen VC-H, Lin N-C, Shao W-C, et al. A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:965\u20139.","DOI":"10.1016\/j.pnpbp.2011.01.015"},{"key":"1000_CR100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1185\/03007995.2012.762903","volume":"29","author":"P Chue","year":"2013","unstructured":"Chue P, Malla A, Bouchard R-H, Lessard S, Ganesan S, Stip E, et al. The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. Curr Med Res Opin. 2013;29:227\u201339.","journal-title":"Curr Med Res Opin"},{"key":"1000_CR101","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/JCP.0b013e3181f28dff","volume":"30","author":"C-H Lin","year":"2010","unstructured":"Lin C-H, Kuo C-C, Chou L-S, Chen Y-H, Chen C-C, Huang K-H, et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol. 2010;30:518\u201325.","journal-title":"J Clin Psychopharmacol"},{"key":"1000_CR102","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00406-010-0142-x","volume":"261","author":"M De Hert","year":"2011","unstructured":"De Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci. 2011;261:231\u20139.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1000_CR103","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0031-1277178","volume":"44","author":"Y-T Xiang","year":"2011","unstructured":"Xiang Y-T, Wang C-Y, Ungvari GS, Kreyenbuhl JA, Chiu HFK, Lai KYC, et al. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. Pharmacopsychiatry. 2011;44:135\u201341.","journal-title":"Pharmacopsychiatry."},{"issue":"1","key":"1000_CR104","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1744-9081-10-35","volume":"10","author":"X Song","year":"2014","unstructured":"Song X, Pang L, Feng Y, Fan X, Li X, Zhang W, Gao J, Zhang J, Nemani K, Zhang H, Lv L. Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. Behav Brain Funct. 2014 Oct 2;10(1):35. https:\/\/doi.org\/10.1186\/1744-9081-10-35.","journal-title":"Behav Brain Funct."},{"key":"1000_CR105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.schres.2018.05.017","volume":"201","author":"X Yuan","year":"2018","unstructured":"Yuan X, Zhang P, Wang Y, Liu Y, Li X, Kumar BU, et al. Changes in metabolism and microbiota after 24-week risperidone treatment in drug na\u00efve, normal weight patients with first episode schizophrenia. Schizophr Res. 2018;201:299\u2013306.","journal-title":"Schizophr Res"},{"key":"1000_CR106","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.schres.2009.12.016","volume":"117","author":"LC Bresee","year":"2010","unstructured":"Bresee LC, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010;117:75\u201382.","journal-title":"Schizophr Res"},{"key":"1000_CR107","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4088\/JCP.08m04718yel","volume":"71","author":"DL Kelly","year":"2010","unstructured":"Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim J-C, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71:304\u201311.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1000_CR108","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamapsychiatry.2019.3377","volume":"77","author":"CU Correll","year":"2020","unstructured":"Correll CU, Kane JM. Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. JAMA Psychiatry. 2020 Mar 1;77(3):225\u20136. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.3377.","journal-title":"JAMA Psychiatry."},{"key":"1000_CR109","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","volume":"80","author":"S Cernea","year":"2020","unstructured":"Cernea S, Dima L, Correll CU, Manu P. Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. Drugs. 2020;80:1763\u201381.","journal-title":"Drugs."},{"issue":"Suppl 3","key":"1000_CR110","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/S0924-9338(05)80182-8","volume":"20","author":"J Bobes","year":"2005","unstructured":"Bobes J, Garc\u00eda-Portilla P, S\u00e1iz PA, Bascar\u00e1n T, Bouso\u00f1o M. Quality of life measures in schizophrenia. Eur Psychiatry J Assoc Eur Psychiatr. 2005;20(Suppl 3):S313\u20137.","journal-title":"Eur Psychiatry J Assoc Eur Psychiatr."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01000-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01000-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01000-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T12:50:52Z","timestamp":1623675052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01000-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01000-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"15 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OA funding note is missing. Funding note should be open access funding provided by Universit\u00e0 Commerciale Luigi Bocconi within the CRUI-CARE Agreement","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 Commerciale Luigi Bocconi within the CRUI-CARE\nAgreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors do not declare any conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Data and materials will be available from the authors upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and\/or code availability"}},{"value":"CJ: Conceptualization; CR, AB: Data curation; CR: Formal analysis; CJ: Funding acquisition; CR, AB: Investigation; CR: Methodology; CJ: Project administration; CJ: Supervision; CJ, CR, AB: Writing\u2014review & editing.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}